Kit for enriching low-abundance protein in blood at high flux and application of kit
By modifying the functional groups of nanomagnetic beads, the high-throughput enrichment of low-abundance proteins in blood is solved, and the problems of low-abundance protein enrichment in the prior art are solved, thus achieving low-throughput and poor sensitivity of low-abundance proteins in blood are achieved Efficient enrichment and accurate analysis of abundance proteins.
Patent Information
- Application Number
- CN202411195940.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-29
AI Technical Summary
The existing low-abundance protein enrichment technology has problems such as low flux, poor sensitivity and low accuracy, which makes it difficult to fully reflect the true composition of proteins in the blood, affecting disease diagnosis and biomarker research.
Nanomagnetic beads modified with "-Si-O-Si-(OR)n-CH2CH2CH2NHCH2CH2NHCH2NH2" functional group were used to enrich the high-throughput of low-abundance proteins in blood, especially the concentration rankings in 2000 to 5000 low-abundance proteins can be efficiently enriched for low-abundance proteins through incubation and cleaning steps.
It significantly improves the enrichment effect of low-abundance protein in blood, can enrich low-abundance proteins with concentrations below 10ng/L at high throughput, improves the enrichment flux and sensitivity, and enhances the low-abundance protein in blood Analytical ability.
Smart Images

Figure CN119043859A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of proteomics detection, and more specifically to a kit for high-throughput enrichment of low-abundance proteins in blood and its application. Background Art
[0002] There are more than 20,000 kinds of proteins in human blood. The detection of changes in protein content in the blood can reflect the health status of the body and the impact of disease or drug exposure on the body. However, the abundance distribution of proteins in the blood is uneven. Some proteins, such as albumin, immunoglobulin G (IgG), transferrin, etc., have very high levels in plasma, while many other proteins have lower levels. Usually, proteins are divided into high-abundance proteins, medium-abundance proteins, and low-abundance proteins according to their concentration or ranking in plasma. Generally speaking, low-abundance proteins refer to proteins with a plasma content below 1 μg / L (ranked after 1837 in the plasma database).
[0003] Although 22 major high-abundance proteins in blood account for 99% of the total blood proteins, Geyer et al.'s study in "Revisiting biomarker discovery by plasma proteomics" shows that the proportion of biomarkers and drug targets in low-abundance proteins is much higher than that of high-abundance proteins. It can be seen that although low-abundance proteins account for less than 1% of the blood, they are of great value in early diagnosis of diseases, prognostic treatment, and biomarker research. For example, some specific low-abundance proteins such as angiogenin have a concentration in plasma below 1μg / L, but they play an important role in disease diagnosis and research. It can be seen that the detection of low-abundance proteins in blood is particularly important, but due to the low content of low-abundance proteins in the blood, specific techniques are usually required for enrichment and then detection and identification analysis.
[0004] The existing enrichment of low-abundance proteins in blood mainly involves removing high-abundance proteins through protein saturation adsorption resin method, PEG precipitation method, chromatography method, target protein antibody method, etc. to obtain low-abundance proteins. However, high-abundance proteins are an important type of carrier in the blood, and a large number of proteins in the blood will bind to high-abundance proteins to achieve transport or exert biological functions. Therefore, when removing high-abundance proteins, some low-abundance proteins bound to high-abundance proteins will also be removed and lost, which can easily lead to distortion of the final identification or quantitative results of low-abundance proteins in the blood, resulting in poor detection accuracy. In addition, this method is difficult to fully reflect the true composition of proteins in the blood, and it is easy to introduce deviations or cause the loss of certain proteins, which limits the widespread application of such methods.
[0005] With the development of liquid biopsy and molecular diagnosis and the increase in detection needs, the technology of enriching low-abundance proteins in body fluid samples such as plasma by nanomagnetic beads in the field of clinical proteomics has gradually emerged internationally, such as patents CN114113287A and CN115449533A. Among them, patent CN 115449533 A discloses a low-abundance protein kit, preparation method and application thereof, which enriches blood proteins based on magnetic graphene oxide particles modified with aminothiourea and sulfonic acid groups. Although it can increase the number of protein identifications compared with the non-enriched group, it does not further analyze the enriched proteins and cannot determine whether it can improve the enrichment effect of low-abundance proteins. A large number of material studies have shown that nanomagnetic bead materials with different modified groups on the surface have different effects on the enrichment of low-abundance proteins in blood, which is mainly reflected in the enrichment depth, type, and enrichment accuracy of low-abundance proteins. Therefore, research on kits and enrichment methods that can more sensitively and high-throughput enrich low-abundance proteins in blood will facilitate a more comprehensive and in-depth analysis of the mechanisms between blood proteins and certain diseases. Summary of the invention
[0006] In view of the above defects or improvement needs of the prior art, the present invention provides a kit for high-throughput enrichment of low-abundance proteins in blood and its application, the purpose of which is to find that the surface of ferroferric oxide microspheres is modified with "-Si-O-Si-(OR)n-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 "(wherein n is independently 0, 1, 2; the -OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 ,) can significantly improve the enrichment effect of low-abundance proteins in the blood, especially the low-abundance proteins whose concentration ranks between 2000 and 5000 in the plasma database, and can enrich low-abundance proteins with a concentration lower than 10 ng / L, thereby solving the technical problem of low enrichment flux of existing nanomagnetic beads for low-abundance proteins in the blood.
[0007] To achieve the above object, according to one aspect of the present invention, a PSA group-modified nanomagnetic bead is provided for use in enriching low-abundance proteins in blood. The PSA group-modified nanomagnetic bead has a core of superparamagnetic nano-iron tetroxide (Fe 3 O 4 ) microspheres, the surface of which is modified with a functional group containing an "N-propylethylenediamine" structure;
[0008] The functional group is "-Si-O-Si-(OR)n-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 ", wherein n is independently 0, 1, or 2; the -OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 .
[0009] Preferably, in the application, the low-abundance blood proteins are proteins ranked between 2000 and 5000 in terms of concentration according to the ranking of protein concentrations in a plasma protein database from high to low.
[0010] Preferably, in the application, the PSA group-modified nanomagnetic beads have -OR as the surface-modified functional group -OCH 3 , or -OCH 2 CH 3 .
[0011] Preferably, the application comprises the following steps:
[0012] The pretreated blood sample is incubated with the PSA group-modified nanomagnetic beads so that the low-abundance proteins are fully bound to the surface of the magnetic beads; after the incubation is completed, the magnetic beads are washed and separated to obtain enriched low-abundance blood proteins;
[0013] The low-abundance proteins include proteins with a concentration of 5 ng / L to 1 μg / L in plasma; preferably, proteins with a concentration of ng level;
[0014] The PSA group-modified nanomagnetic beads have a particle size of 50-500 nm and a concentration of 1-10 mg / mL.
[0015] Preferably, in the application, the pretreated blood sample is obtained according to the following method:
[0016] Fresh or thawed blood samples are centrifuged and the supernatant is collected, and the binding solution is added and mixed to obtain a pretreated blood sample;
[0017] The binding solution includes 5-10 mM Tris-HCl, 0.5-2 mM EDTA and 0.05%-2% CHAPS by mass.
[0018] Preferably, in the application, the binding solution further comprises one or more combinations of PBS, sodium hydroxide, potassium hydroxide, SDS, acetonitrile, ethanol, and Tween, wherein the concentration of potassium hydroxide or sodium hydroxide is 0.5-1 mM, and the volume percentage of ethanol is 1%-10%.
[0019] Preferably, in the application, the nanomagnetic beads modified with PSA groups have a particle size of 100-300 nm; and the incubation is carried out at 20-37° C. and with shaking for 5-60 min.
[0020] According to another aspect of the present invention, a kit for high-throughput enrichment of low-abundance proteins in blood is also provided, which comprises nanomagnetic beads modified with PSA groups and a binding solution;
[0021] The PSA group-modified nanomagnetic beads, the nanoFe 3 O 4 The surface of the microspheres is modified with functional groups containing an "N-propylethylenediamine" structure;
[0022] The functional group is "-Si-O-Si-(OR)n-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 ", wherein n is independently 0, 1, or 2; the -OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 .
[0023] Preferably, in the kit, the nanomagnetic beads modified with the PSA group have a particle size of 50-500 nm, and the -OR in the surface modified functional group is -OCH 3 、-OCH 2 CH 3 .
[0024] Preferably, the binding solution of the kit comprises 5-10 mM Tris-HCl, 0.5-2 mM EDTA and 0.05%-2% CHAPS by mass.
[0025] In general, compared with the prior art, the above technical solution conceived by the present invention can achieve the following beneficial effects due to the nanomagnetic beads modified with PSA groups used in the present invention:
[0026] The present invention found that the surface of the ferroferric oxide microspheres is modified with "-Si-O-Si-(OR)n-CH2 CH 2 CH 2 NHCH 2 CH 2 NH 2 ”(Where -OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 ) have a high-throughput enrichment effect on low-abundance proteins in blood, especially compared with the existing commercially available MAX strong negative ion group-modified nanomagnetic beads (enrichment of proteins ranked within 2000), it can high-throughput enrich low-abundance proteins ranked between 2000 and 5000 in the plasma protein database, especially low-abundance proteins with a concentration of ng level in plasma. This method can be used to enrich low-abundance proteins with a concentration of less than 10 ng / L in human plasma. It not only has high enrichment flux but also high sensitivity and good stability, and can be used for high-throughput enrichment of low-abundance proteins in blood. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 are the identification results of plasma proteins and fetal bovine serum proteins in the unenriched group, other commercial magnetic beads enriched group, and PSA magnetic beads enriched group, where A is the number of plasma proteins identified in each group, B is the distribution among the enriched plasma proteins in the three groups, and C is the distribution among the enriched fetal bovine serum proteins in the three groups;
[0028] Figure 2 It is a scatter plot and a bar graph of the identification of enriched plasma proteins, where A is the identification result of non-enriched histones, B is the identification result of commercial magnetic beads enriched histones, C is the identification result of PSA magnetic beads enriched histones, and D is the quantitative distribution of different groups of enriched plasma proteins in different concentration ranges;
[0029] Figure 3 is the distribution of coefficient of variation of protein quantitative values of biological replicates within different treatment groups;
[0030] Figure 4 It is the quantitative ratio distribution result of plasma protein, E.coli protein and BSA protein in different groups, where A is the ridge plot and B is the scattered bar graph;
[0031] Figure 5Are the results of correlation analysis between proteins, where A is the correlation analysis between non-enriched group plasma proteins and PSA magnetic bead enriched group plasma proteins, B is the correlation analysis between non-enriched group plasma proteins and plasma proteins in the existing plasma database, C is the correlation analysis between PSA magnetic bead enriched group plasma proteins and plasma proteins in the existing plasma database, and D is the correlation analysis between Hela cell proteins and plasma proteins in the plasma database. DETAILED DESCRIPTION
[0032] In order to further explain the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the specific implementation mode, structure, characteristics and effects of the present invention are described in detail below in combination with the accompanying drawings and preferred embodiments.
[0033] Low-abundance plasma proteins generally refer to a class of proteins with a content of less than 1 μg / L in plasma. Although they account for less than 1% of the plasma content, they are of great value in early diagnosis of diseases, prognosis and treatment, and biomarker research. However, since the content of high-abundance proteins in plasma exceeds 99%, the detection and analysis of these low-abundance proteins are relatively difficult, resulting in existing methods for enriching low-abundance blood proteins, such as single enrichment type, low throughput, or poor enrichment sensitivity.
[0034] The present invention finds that PSA nanomagnetic beads modified with functional groups containing an "N-propylethylenediamine" structure have a significant effect on improving low-abundance proteins in blood. Compared with the existing commercially available MAX strong anionic group-modified nanomagnetic beads, the number of low-abundance proteins in the enriched proteins is increased by 308%, the enrichment flux is high, and low-abundance proteins with a concentration lower than 10ng / L can be enriched, the sensitivity is high, and it can be used for high-throughput enrichment of low-abundance proteins in blood. The functional group containing the "N-propylethylenediamine" structure is "-Si-O-Si-(OR)n-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 ", wherein n is independently 0, 1, or 2; the -OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 .
[0035] Based on this, the present invention provides an application of PSA group-modified nanomagnetic beads in enriching low-abundance proteins in blood.
[0036] The PSA group-modified nanomagnetic beads (referred to as PSA nanomagnetic beads) have a core composed of superparamagnetic nano-Fe 3 O 4 Microspheres, the surface of which is modified with a functional group containing an "N-propylethylenediamine" structure;
[0037] The functional group is "-Si-O-Si-(OR)n-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 ", wherein n is independently 0, 1, or 2; the -OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 .
[0038] When blood proteins encounter the PSA group-modified nanomagnetic beads, their high-abundance proteins will first be adsorbed on the surface of the nanomagnetic bead material, gradually forming a "protein corona". Since the "N-propylethylenediamine" part of the functional group modified on the surface of the nanomagnetic beads interacts better with low-abundance proteins, the low-abundance proteins in the blood gradually replace the high-abundance proteins, thereby achieving high-throughput enrichment of low-abundance proteins in the blood.
[0039] Preferably, the functional group -OR is -OCH 3 , or -OCH 2 CH 3 .
[0040] The nanomagnetic beads have a particle size of 50-500nm, preferably 100-300nm.
[0041] The low-abundance protein is a protein with a concentration in plasma below 1 μg / L. In the present invention, the low-abundance protein also includes a protein with a concentration below 10 ng / L, or a low-abundance protein ranked after 2000 in the plasma database (Human Blood Protein Atlas), preferably a low-abundance protein ranked between 2000 and 5000, wherein the protein concentration ranking in the plasma database (Human Blood Protein Atlas) is from high to low.
[0042] The application specifically comprises the following steps:
[0043] The pretreated blood sample is incubated with the nanomagnetic beads modified with the PSA group of the present invention so that the low-abundance proteins are fully bound to the surface of the magnetic beads; after the incubation is completed, the magnetic beads are washed and separated to obtain the enriched low-abundance proteins in the blood;
[0044] The core of the PSA group-modified nanomagnetic beads is superparamagnetic nano-iron tetroxide (Fe 3 O 4 ) microspheres, the surface of which is modified with a functional group containing an "N-propylethylenediamine" structure;
[0045] The functional group containing the "N-propylethylenediamine" structure is "-Si-O-Si-(OR)
[0046] n-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 ", wherein n is independently 0, 1, 2; said -
[0047] OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 ; The particle size of its nanomagnetic beads is 50-500nm.
[0048] In some embodiments, the PSA group-modified nanomagnetic beads preferably have a surface-modified functional group in which -OR is -OCH 3 , or -OCH 2 CH 3 More preferably, the PSA group-modified nanomagnetic beads have a particle size of 100-300 nm and a concentration of 1-10 mg / mL.
[0049] The incubation was carried out at 20-37°C with shaking for 5-60 min.
[0050] The pretreated blood sample is obtained according to the following method:
[0051] Fresh or thawed blood samples are centrifuged, the supernatant is collected, and a binding solution is added and mixed to obtain a pretreated blood sample; the binding solution includes 5-10mM Tris-HCl, 0.5-2mM EDTA and 0.05%-2% CHAPS by mass, which are added according to a preset ratio.
[0052] Preferably, the binding solution further comprises one or more combinations of PBS, sodium hydroxide, potassium hydroxide, SDS, acetonitrile, ethanol, and Tween, wherein the concentration of potassium hydroxide or sodium hydroxide is 0.5-1 mM, and the volume percentage of ethanol is 1%-10%.
[0053] In some embodiments, the binding solution is 10 mM Tris-HCl, 1 mM EDTA, and 0.05% CHAPS by mass concentration, and is added according to a volume ratio of blood sample to binding solution of 1:4-5.
[0054] In addition, the present invention also provides a kit for high-throughput enrichment of low-abundance proteins in blood, the kit comprising nanomagnetic beads modified with PSA groups and a binding solution;
[0055] The core of the PSA group-modified nanomagnetic beads is superparamagnetic nano-iron tetroxide (Fe 3 O 4 ) microspheres, the surface of which is modified with a functional group containing an "N-propylethylenediamine" structure; the functional group is "-Si-O-Si-(OR)n-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 ", wherein n is independently 0, 1, or 2; the -OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 .
[0056] Preferably, the -OR is -OCH 3 , or -OCH 2 CH 3 .
[0057] The binding solution includes 5-10 mM Tris-HCl, 0.5-2 mM EDTA and 0.05%-2% CHAPS by mass.
[0058] Preferably, the kit has a particle size of 50-500 nm of nanomagnetic beads modified with PSA groups. More preferably, the binding solution further comprises one or more combinations of PBS, sodium hydroxide, potassium hydroxide, SDS, acetonitrile, ethanol, and Tween, wherein the concentration of potassium hydroxide or sodium hydroxide is 0.5-1 mM, and the volume percentage of ethanol is 1%-10%.
[0059] The following are examples
[0060] Example 1 Preparation method of PSA group-modified nanomagnetic beads
[0061] In this embodiment, superparamagnetic nanospheres of ferroferric oxide (Fe 3 O 4 ) surface undergoes silanization reaction to bond with functional groups containing the structure of "N-propylethylenediamine", where the functional group is "-Si-O-Si-(OR)n-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 ", wherein n is independently 0, 1, or 2; the -OR is -OCH 3 、-OCH 2 CH 3 , or -OCH 2 CH 2 CH 3 .
[0062] The details are as follows:
[0063] Weigh 1.0g Fe 3 O 4 Join in 1000mL three-necked flask, add 400mL ethanol and 100mL deionized water, ultrasonic dispersion.In above-mentioned suspension, add 4mL ammoniacal liquor.Under mechanical stirring condition, drip 4mL tetraethyl orthosilicate, stirring reaction 2 hours under room temperature condition.Continue to drip 4mL PSA silanization reagent (N-aminoethyl-3-aminopropyl triethoxysilane) in above-mentioned reaction system subsequently, and continue reaction 6 hours.After reaction finishes, magnetic material is separated with magnet, and washed with water and ethanol, can obtain the nanometer magnetic bead modified by PSA group after vacuum drying, be abbreviated as PSA nanometer magnetic bead or PSA magnetic bead, its particle diameter is 100-300nm, and the kernel of the nanometer magnetic bead modified by its PSA group is superparamagnetic nanometer ferroferric oxide (Fe 3 O 4 ) microspheres, the functional groups modified on the surface of the microspheres are "-Si-O-Si-(OCH 2 CH 3 )n-(CH 2 ) 3 NH(CH 2 ) 2 NH 2 ”, where n is 0, 1, or 2 independently.
[0064] In this embodiment, Fe 3 O 4 Commercially available magnetic Fe 3 O 4, Fe can also be synthesized as follows 3 O 4 :
[0065] Weigh 5.0g of ferric chloride hexahydrate, dissolve it in 100mL ethylene glycol (in a 200mL beaker), and dissolve it by ultrasonic. Weigh 15g of anhydrous sodium acetate and 50mL of ethylenediamine, add the above ferric chloride ethylene glycol solution, and stir mechanically for 30min. Then pour the above uniformly dispersed solution into a 200mL teflon high-pressure reactor and react at 200℃ for 8h. After the reactor cools to room temperature, wash it with water and ethanol, and then vacuum dry it to obtain the product Fe 3 O 4 .
[0066] In addition, in the preparation of the PSA group-modified nanomagnetic beads described in the present invention, the PSA silanization reagent can also be replaced with a PSA silanization reagent containing different siloxanes, such as N-aminoethyl-3-aminopropyldimethylmethoxysilane, N-aminoethyl-3-aminopropylmethyldimethoxysilane, N-aminoethyl-3-aminopropyltrimethoxysilane, etc., to obtain PSA nanomagnetic beads synthesized from different raw materials, wherein -OR in the functional group is -OCH 3 or -OCH 2 CH 2 CH 3 .
[0067] The key part of the PSA group-modified nanomagnetic beads in the present invention for the interaction with proteins is the "N-propylethylenediamine" part (-CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 )
[0068] The difference in the choice of silane reagent lies in the different alkyl groups bound to the silicon-oxygen bond, such as methoxy, ethoxy or propoxy, but there is no obvious difference in the binding effect of PSA magnetic beads on specific proteins.
[0069] Example 2 Comparison of the enrichment effects of different nanomagnetic beads on low-abundance proteins in blood
[0070] The control group was not enriched with magnetic beads. This example compared the PSA nanomagnetic beads prepared in Example 1 (the surface modified functional group -OR is -OCH 2 CH 3 ) and other commercially available magnetic beads (MAX strong negative ion group modified nanomagnetic beads) on the enrichment effect of low-abundance proteins in the blood samples to be tested, wherein the blood samples to be tested include human plasma and fetal bovine serum, as follows:
[0071] Prepare nanomagnetic bead suspension: weigh a certain amount of PSA nanomagnetic beads or commercial MAX magnetic beads, add 1 mL ddH 2 O, wash and resuspend the magnetic beads by ultrasound, repeat 2 times. Add a certain volume of binding solution (10mM Tris, 1mM EDTA, 0.05% CHAPS, wherein CHAPS is a non-denaturing zwitterionic detergent, and its chemical name is 3-[(3-cholamidopropyl) dimethylammonium] propanesulfonate) to the washed magnetic beads, so that the final magnetic bead suspension concentration is 1-10mg / mL.
[0072] Pretreatment of the blood samples to be tested: thaw the blood samples to be tested (human plasma or fetal bovine serum) in a 4°C refrigerator, centrifuge at 4°C and 2000g for 10 minutes, take 20 μL of supernatant into a 1.5 mL tube, and temporarily store at 4°C to avoid obtaining flocculent precipitates during subsequent tests, which will affect the enrichment and detection results; divide the pretreated human plasma samples into 3 equal groups (non-enriched group, PSA magnetic bead enriched group, commercial nanomagnetic bead enriched group), and divide the pretreated fetal bovine serum samples into 3 equal groups (non-enriched group, PSA magnetic bead enriched group, commercial nanomagnetic bead enriched group).
[0073] The human plasma samples that were not enriched with magnetic beads were used as control group 1, also referred to as the non-enriched group.
[0074] Add 80 μL of binding solution to the other two groups of human plasma samples respectively and mix them; then add 100 μL of 10 mg / mL PSA nanomagnetic bead suspension and commercial nanomagnetic bead suspension respectively and mix them; the binding solution includes 5-10 mM Tris-HCl, 0.5-2 mM EDTA and 0.05%-2% CHAPS by mass, and preferably also includes one or more combinations of PBS, sodium hydroxide, potassium hydroxide, SDS, acetonitrile, ethanol, and Tween, wherein the concentration of potassium hydroxide or sodium hydroxide is 0.5-1 mM, and the volume percentage of ethanol is 1%-10%.
[0075] The fetal bovine serum samples that were not enriched with magnetic beads were used as control group 2, recorded as non-enriched group. 80 μL of binding solution was added to the other two groups of fetal bovine serum, and mixed well; then 100 μL of PSA nanomagnetic bead suspension and commercial nanomagnetic beads were added, and mixed well; the binding solution was the same as above.
[0076] The specific processing steps for the control group without magnetic bead enrichment are as follows:
[0077] Thaw human plasma or fetal bovine serum in a 4°C refrigerator, centrifuge at 4°C and 2000 g for 10 min, and transfer the supernatant to a 1.5 mL tube.
[0078] Take 10 μL of the above supernatant and add it to 190 μL of SDC++ solution, mix well, shake in a 60°C metal bath for 30 min, cool to room temperature, centrifuge, take the supernatant and transfer it to a new 1.5 mL tube, and use the Bradford method for protein quantification.
[0079] Take 50 μg of protein into a new 1.5 mL tube and add SDC++ solution to 100 μL; add the same volume of ddHO 2 O, so that the SDC concentration drops below 0.5%.
[0080] 1 μg of Trypsin was added, and the mixture was incubated at 37°C with shaking overnight for enzymatic hydrolysis. After the overnight enzymatic hydrolysis, TFA was added to terminate the enzymatic cleavage, and the supernatant was desalted by SDB-RPS desalting column, vacuum-dried, and frozen at -20°C.
[0081] The above groups of samples are placed under 20-37°C temperature conditions and shaken for 5-60 minutes to allow the proteins in the blood samples to be fully bound to the surface of the magnetic beads. For example, in this embodiment, the incubation condition is selected from 37°C incubation and shaking for 60 minutes.
[0082] After incubation, place the EP tube on the magnetic rack for 2 minutes, separate the magnetic beads, and discard the supernatant; add 200 μL of washing solution (10 mM Tris, 1 mM EDTA) to the magnetic beads, vortex for 5 minutes, place the EP tube on the magnetic rack for 2 minutes, separate the magnetic beads, discard the supernatant, repeat 3 times, and the protein bound to the magnetic beads is the protein enriched in the blood sample to be tested.
[0083] Denaturation and reductive alkylation of enriched proteins: Add 100 μL of SDC++ solution (1% SDC, 10 mM TCEP, 40 mM CAA, 100 mM Tris-HCl) to the magnetic beads bound to the above proteins, heat at 95°C for 10 min to denature and reductively alkylate the proteins; when the solution temperature drops to room temperature, add an equal volume of ddH 2 O, reducing the SDC concentration to 0.5%.
[0084] Identification of enriched proteins: Add 1 μg of Trypsin, incubate at 37°C with shaking overnight for enzymatic hydrolysis; after overnight enzymatic hydrolysis, add TFA to terminate the enzyme cleavage, take the supernatant and desalt it on a SDB-RPS desalting column, vacuum dry it and freeze it at -20°C. Use mass spectrometry for quantitative detection and identification, as follows:
[0085] ①Instrument system: TimsTOF pro mass spectrometer connected to UltiMate 3000RSLCnano liquid phase liquid chromatography-mass spectrometry system.
[0086] ②Chromatographic column: 15cm long C18 chromatographic column.
[0087] ③Mobile phase: A-0.1% formic acid; B-0.1% formic acid, acetonitrile.
[0088] ④Flow rate: 300nL / min.
[0089] ⑤Injection volume: 50μL dissolved sample, injection volume 3μL.
[0090] ⑥Data acquisition mode: data-independent DIA acquisition mode.
[0091] The DIANN (v1.8.1) software was used to search the database of the mass spectrometry raw data to obtain the identification results of each group of proteins and peptides, such as Figure 1 shown.
[0092] Figure 1 The results are for the identification of plasma proteins and fetal bovine serum albumin in the unenriched group, other commercial magnetic beads enriched group, and PSA magnetic beads enriched group. Figure 1 As shown in Figure A, the number of plasma proteins and fetal bovine serum proteins identified in the PSA magnetic bead enrichment group was significantly higher than that in the other two groups. Figure 1 As can be seen from Figures B and C, compared with the non-enriched group and other commercial magnetic beads enriched groups, the PSA magnetic beads enriched group identified 532 new types of plasma proteins, and the PSA magnetic beads enriched group identified 940 new types of fetal bovine serum proteins, indicating that PSA magnetic beads can enrich more proteins in the blood. It is speculated that these proteins may be some low-abundance proteins that are difficult to enrich.
[0093] In order to further confirm whether the new protein enriched by PSA magnetic beads is a low-abundance plasma protein, this example refers to the actual plasma protein concentration data provided by the human blood proteins database, and draws a scatter plot and a bar graph of plasma protein identification. The results are as follows: Figure 2 As shown, Figure 2 A is the identification result of non-enriched histones, B is the identification result of commercial magnetic beads enriched histones, and C is the identification result of PSA magnetic beads enriched histones. The gray dots represent plasma proteins from the database; the red dots represent plasma proteins identified in proteins enriched by different magnetic beads, and the horizontal axis represents the actual concentration ranking of plasma proteins. The lower the ranking, the lower the actual concentration of the plasma protein. For example, a plasma protein with a concentration of 1ug / L in the plasma database ranks 1837th; the vertical axis represents the logarithmic value of the concentration of plasma proteins from the database. The larger the value, the higher the actual concentration of the plasma protein.
[0094] Depend on Figure 2From the identification results of A, B, and C proteins, we can see that the proteins in the non-enriched group are mainly ranked in the top 1000. It can be seen that the proteins not enriched with magnetic beads are mainly high-abundance proteins, and almost no low-abundance proteins are enriched; the proteins enriched in the commercial magnetic beads enrichment group are mainly ranked in the top 2000. It can be seen that the proteins enriched with commercial magnetic beads are also mainly high-abundance proteins, and very few low-abundance proteins are enriched; and the proteins enriched in the PSA magnetic beads enrichment group include more low-abundance proteins ranked 2000-4000.
[0095] After matching with the plasma protein database (https: / / www.proteinatlas.org / humanproteome / blood+protein / proteins+detected+in+ms), the number of protein concentrations enriched in different groups was calculated. Figure 2 As shown in D.
[0096] Figure 2 In the middle D, the number of proteins corresponding to the horizontal axis ng / L represents the number of proteins with a concentration lower than 1μg / L, that is, the number of enriched low-abundance proteins, while the number of proteins corresponding to the horizontal axis μg / L represents the number of proteins with a concentration of 1μg / L to 980μg / L (including 1μg / L), and the number of proteins corresponding to mg / L represents the number of proteins with a concentration of 1mg / L to 440mg / L.
[0097] Since it is necessary to match the identified proteins with the database, some proteins are not matched. In this example, the proteins that overlap or match with the database are specifically analyzed, not just these proteins that are actually identified. Figure 2 From the distribution of the enriched plasma proteins in each group in D after matching with the database, it can be seen that the total number of plasma proteins matched by the non-enriched group is 378, of which the total number of low-abundance proteins is 9, and the lowest concentration of low-abundance proteins is 16ng / L; the total number of plasma proteins matched by the commercial nanomagnetic bead enriched group is 579, of which the total number of low-abundance proteins is 57, and the lowest concentration of low-abundance proteins is 22ng / L; and the total number of plasma proteins matched by the PSA magnetic bead enriched group is 992, of which the total number of low-abundance proteins is 233, and the concentration of low-abundance proteins is as low as 7ng / L, and the ranking of this low-abundance protein in the plasma database is 4044. It can be seen that compared with the non-enriched group, the number of low-abundance proteins enriched by this method is 25.8 times and 4 times that of the non-enriched group and the commercial nanomagnetic bead enriched group, respectively. Compared with the existing commercially available nanomagnetic beads, the number of low-abundance proteins enriched by PSA magnetic beads has increased by 308%. This indicates that PSA magnetic beads can enrich low-abundance proteins in plasma with high throughput, especially low-abundance proteins ranked between 2000-4000, and can be used to enrich low-abundance proteins in blood.
[0098] Example 3 PSA nanomagnetic beads can enrich low-abundance proteins in blood with high stability
[0099] In order to further verify that the PSA group-modified nanomagnetic beads can enrich low-abundance proteins in blood, this example selected 3 different batches of human plasma, and compared the commercial magnetic beads (nanomagnetic beads modified with MAX strong anionic groups) and PSA nanomagnetic beads (the -OR in the surface-modified functional group is -OCH 3 )Differential enrichment of blood proteins.
[0100] The treatment of the control group without magnetic bead enrichment was the same as in Example 2;
[0101] Commercial magnetic beads enrichment group: same as Example 2;
[0102] PSA nanomagnetic beads enrichment group: the same as Example 2 except that the PSA magnetic beads used for enrichment were different.
[0103] The mass spectrometry detection conditions and mass spectrometry raw data database search and analysis and identification methods for each group are the same as those in Example 2. The identification results of each group of enriched proteins are as follows:
[0104] Table 1 Number of low-abundance proteins in the enriched proteins of human plasma samples that matched the database
[0105]
[0106] The above results indicate that the PSA nanomagnetic beads with surface modified functional groups containing the "N-propylethylenediamine" structure have a good enrichment effect on low-abundance proteins in the blood and can be used to enrich low-abundance proteins in the blood.
[0107] In addition, this example also studies the distribution of the coefficient of variation of the protein quantitative values of biological replicates in different treatment groups. Figure 3 shown.
[0108] Depend on Figure 3 It can be seen that the coefficient of variation CV value of the PSA magnetic beads enrichment group is about 2%, indicating that the method of enriching low-abundance proteins in blood using PSA magnetic beads has good stability.
[0109] The coefficient of variation (CV) is a dimensionless indicator used in statistics to measure the degree of data dispersion. It represents the ratio of the standard deviation of the data to its mean. In the case of protein quantitative values, the coefficient of variation can be used to evaluate the accuracy and repeatability of protein measurements. The specific calculation formula for the coefficient of variation is as follows:
[0110]
[0111] Where:
[0112] σ is the standard deviation of the data;
[0113] μ is the mean of the data.
[0114] Usually, a CV value less than 10% indicates that the discreteness between the measured values is small, and the measurement accuracy and repeatability are high; while a CV value greater than 30% indicates that the discreteness between the measured values is large, and the measurement accuracy and repeatability are low.
[0115] According to the above formula, the median of the coefficient of variation of the protein quantitative values of biological replicates in the group enriched with the PSA magnetic beads is 2-3%, of which 90% of the proteins have a coefficient of variation below 5%, and more than 99% of the proteins have a coefficient of variation below 10%. A very small number of proteins may have a coefficient of variation exceeding 10% due to various uncertain factors in the experimental process. It can be seen that the method for enriching low-abundance plasma proteins based on PSA provided by the present invention has high accuracy and stability.
[0116] Example 4 Study on the accuracy of the method for enriching low-abundance proteins in blood using PSA nanomagnetic beads
[0117] Most existing methods related to enrichment of low-abundance proteins in blood generally remove high-abundance proteins first and then enrich low-abundance proteins. However, when removing high-abundance proteins, many bound low-abundance proteins will also be removed and lost, which can easily lead to distortion of the final quantitative results of low-abundance proteins in blood and poor accuracy. In order to explore the accuracy of the PSA nanomagnetic beads used in the enrichment method of low-abundance proteins in blood, this example uses human plasma, E. coli, and BSA samples to study its accuracy in enriching low-abundance proteins in blood, as follows:
[0118] The human plasma samples were thawed in a 4°C refrigerator, centrifuged at 4°C and 2000 g for 10 min, and the supernatant was transferred to a 1.5 mL tube to obtain pretreated plasma;
[0119] Prepare 6 1.5 mL tubes respectively, add 20 μL plasma, 0.2 μg E. coli, and 0.8 μg BSA protein to 3 of the 1.5 mL tubes respectively, and mark them as Enrich-A1, Enrich-A2, and Enrich-A3, abbreviated as A1, A2, and A3; add 20 μL plasma, 0.8 μg E. coli, and 0.2 μg BSA protein to the other 3 1.5 mL tubes respectively, and mark them as Enrich-B1, Enrich-B2, and Enrich-B3, abbreviated as B1, B2, and B3.
[0120] Add 80 μL of binding solution to the Enrich group samples, mix thoroughly, and then take 5 μL of solution from each 1.5 mL tube into new 1.5 mL tubes, which are marked as Raw-A1, Raw-A2, Raw-A3, Raw-B1, Raw-B2, and Raw-B3 respectively.
[0121] The protein enrichment of the samples in the Enrich group was carried out by the PSA magnetic bead enrichment method in Example 2; the protein enrichment of the samples in the Raw group was carried out by the enrichment method without magnetic beads in Example 3.
[0122] For samples from groups A and B, theoretically, the ratio of plasma protein between group A1 and group B1 is 1:1, the ratio of E. coli protein between group A2 and group B2 is 1:4, and the ratio of BSA protein between group A3 and group B3 is 4:1.
[0123] The quantitative ratios of the above plasma proteins, E. coli proteins, and BSA proteins in different groups were detected as follows: Figure 4 shown.
[0124] Figure 4 In the figure, A is a ridge plot and B is a scattered bar graph. Ignoring errors in peptide preparation, mass spectrometry loading, etc., the protein quantitative ratios of group A and group B should ideally be completely consistent with the above ratios. However, in actual experiments, it is normal for the quantitative ratios to fluctuate around the theoretical values.
[0125] Depend on Figure 4 It can be seen that the quantitative ratios of E. coli, BSA and plasma proteins in group A and group B, log2(B / A), of the Enrich group are close to the corresponding ratios of the Raw group and close to the theoretical values, indicating that the method based on PSA nanomagnetic beads to enrich low-abundance proteins in blood has high accuracy and PSA nanomagnetic beads can be used to enrich low-abundance proteins in blood.
[0126] In addition, for human plasma samples, this embodiment also uses Hela cell protein as a negative control, wherein the Hela cell protein detection data is obtained by extracting the protein of the Hela cell sample, enzymatically hydrolyzing the peptide fragments and then performing mass spectrometry detection, but its preparation process does not require PSA magnetic bead enrichment.
[0127] Furthermore, the correlation between the plasma proteins enriched in the PSA magnetic bead enrichment group and the non-enrichment group, the correlation between the plasma proteins enriched in the non-enrichment group and the plasma proteins in the plasma database (Human Blood Protein Atlas), the correlation between the plasma proteins enriched in the PSA magnetic bead enrichment group and the plasma proteins in the plasma database, and the correlation between the Hela cell proteins and the plasma proteins in the plasma database were analyzed. The analysis results are as follows: Figure 5shown.
[0128] The plasma database described in this embodiment is from the website
[0129] https: / / v19.proteinatlas.org / humanproteome / blood / proteins+detected+in +ms The reason for selecting this database is that Human Protein Atlas is a very authoritative database on human protein distribution and expression (HPA for short), and many high-quality articles have cited this database; secondly, the plasma database Human Blood Protein Atlas cited in the present invention is a component of the HPA database, especially summarizing the human plasma proteins detected by mass spectrometry in different literature studies.
[0130] Figure 5 Figure A in the figure is the correlation analysis between the plasma proteins in the non-enriched group and the plasma proteins in the PSA magnetic beads enriched group, where R=0.5367. It can be seen that the correlation between the plasma proteins enriched by PSA magnetic beads and those not enriched by magnetic beads is low. This is mainly because the plasma proteins obtained in the non-enriched group without magnetic beads enrichment are mainly high-abundance proteins that are easy to collect, while the plasma proteins enriched by PSA magnetic beads include not only high-abundance proteins but also more low-abundance proteins. However, since it is difficult to separate and purify low-abundance proteins from enriched plasma proteins, only all overlapping proteins can be used in the analysis. The correlation between the two is low, which indirectly shows that the plasma proteins enriched by PSA magnetic beads include not only high-abundance proteins but also low-abundance proteins.
[0131] Figure 5 Figure B is the correlation analysis between the plasma proteins in the non-enriched group and the plasma proteins in the existing plasma database, where R=0.7265. It can be seen that the correlation between the plasma proteins in the non-enriched group and the plasma proteins in the existing plasma database is high, indicating that the plasma proteins in the non-enriched group are mainly high-abundance proteins in the existing plasma database.
[0132] Figure 5 Middle C is the correlation analysis between the plasma proteins in the PSA magnetic bead enriched group and the plasma proteins in the existing plasma database, where R=0.6648. Compared with the correlation analysis between the plasma proteins in the non-enriched group, the R value is higher and the correlation is better. This is mainly because the plasma proteins in the existing plasma database include high-abundance proteins and low-abundance proteins, while the plasma proteins in the non-enriched group are mainly high-abundance proteins. This also indirectly shows that the plasma proteins enriched by PSA magnetic beads include low-abundance proteins, and may even include some low-abundance proteins that have not been identified in the plasma database, but this embodiment does not make further identification and in-depth analysis.
[0133] Figure 5D is the correlation analysis between Hela cell protein and plasma protein in the plasma database, and its R = 0.0688. It can be seen that not all quantitative values of human proteins are positively correlated with the quantitative values of proteins in the plasma database. First, it shows that the plasma database used in this example is reliable and reliable, and secondly, it indirectly shows the method of enriching low-abundance proteins in blood by PSA magnetic beads and the accuracy of quantitative detection.
[0134] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.
Claims
1. Application of PSA group-modified nanomagnetic beads in enrichment of low-abundance proteins in blood, characterized in that: The PSA group-modified nanomagnetic beads have a core composed of superparamagnetic nano-Fe3O4 microspheres, and the surface of the microspheres is modified with a functional group containing an "N-propylethylenediamine" structure; The functional group is "-Si-O-Si-(OR)n-CH2CH2CH2NHCH2CH2NH2", wherein n is independently 0, 1, or 2; and the -OR is -OCH3, -OCH2CH3, or -OCH2CH2CH3.
2. The use according to claim 1, characterized in that According to the ranking of protein concentrations from high to low in the plasma protein database, the low-abundance blood proteins are proteins ranked between 2000 and 5000 in concentration.
3. The use according to claim 2, characterized in that In the PSA group-modified nanomagnetic beads, the -OR functional group modified on the surface is -OCH3 or -OCH2CH3.
4. The use according to any one of claims 1 to 3, characterized in that: The application comprises the following steps: The pretreated blood sample is incubated with the PSA group-modified nanomagnetic beads so that the low-abundance proteins are fully bound to the surface of the magnetic beads; after the incubation is completed, the magnetic beads are washed and separated to obtain enriched low-abundance blood proteins; The low-abundance proteins include low-abundance proteins with a concentration of 5 ng / L to 1 μg / L in the plasma protein database; The PSA group-modified nanomagnetic beads have a particle size of 50-500 nm and a concentration of 1-10 mg / mL.
5. The use according to claim 4, characterized in that The pretreated blood sample is obtained according to the following method: Fresh or thawed blood samples are centrifuged and the supernatant is collected, and the binding solution is added and mixed to obtain a pretreated blood sample; The binding solution includes 5-10 mM Tris-HCl, 0.5-2 mM EDTA and 0.05%-2% CHAPS by mass.
6. The use according to claim 5, characterized in that The binding solution also includes one or more combinations of PBS, sodium hydroxide, potassium hydroxide, SDS, acetonitrile, ethanol, and Tween, wherein the concentration of potassium hydroxide or sodium hydroxide is 0.5-1mM, and the volume percentage of ethanol is 1%-10%.
7. The use according to claim 5 or 6, characterized in that The nanomagnetic beads modified with the PSA group have a particle size of 100-300 nm; the incubation is performed at 20-37° C. and oscillated for 5-60 min.
8. A kit for high-throughput enrichment of low-abundance proteins in blood, characterized in that: It includes nanomagnetic beads modified with PSA groups and a binding solution; The PSA group-modified nanomagnetic beads have a core of nano-Fe3O4 microspheres, and the surface of the microspheres is modified with functional groups containing an "N-propylethylenediamine" structure; The functional group is "-Si-O-Si-(OR)n-CH2CH2CH2NHCH2CH2NH2", wherein n is independently 0, 1, or 2; and the -OR is -OCH3, -OCH2CH3, or -OCH2CH2CH3.
9. The kit according to claim 8, characterized in that The nanomagnetic beads modified with the PSA group have a particle size of 50-500 nm, and the -OR in the functional group modified on the surface of the microspheres is -OCH3 or -OCH2CH3.
10. The kit according to claim 9, characterized in that The binding solution includes 5-10 mM Tris-HCl, 0.5-2 mM EDTA and 0.05%-2% CHAPS by mass.
Citation Information
Cited By
Nanometer magnetic bead based on polyamino acid material, preparation method of nanometer magnetic bead and application of nanometer magnetic bead in early cancer screening
CN122006677A
A kind of nano magnetic bead based on polyamino acid material, its preparation method and its application in early screening of cancer
CN122006677B
